Enrichment of GO and KEGG pathways showed that inflammatory and immune-regulatory pathways were considerably involved, the PI3K-Akt signalling pathway in particular.
Multi-Target Pharmacological Evaluation of Embelin and Piperine against Rheumatoid Arthritis: A Network Pharmacology and Molecular Docking Study
Sulaiman Ahmad, Shaikh Mahmad kaif, Shaikh Mehmood Dawood
- Editor approved · 16 Nov 2026
- June 2026
- DOI 10.56511/jipbs.2026.13106
The question
What might Embelin and Piperine do against rheumatoid arthritis, and through which targets?
- Rheumatoid arthritis is a lasting autoimmune inflammatory illness: the joint lining inflames, cartilage wears away, joints deteriorate and disability grows.
- Conventional approaches are often tied to side effects and weak long-term success, which has prompted a search for safer plant treatments acting on several targets at once.
What was done
- Network pharmacology and molecular docking were brought together to examine what the two compounds might do against arthritis.
- Likely targets of the two compounds were found with SwissTargetPrediction and PubChem; the targets tied to rheumatoid arthritis came from the GeneCards database.
- The targets common to both sides were then studied in protein-protein interaction networks, to pick out the critical hub genes.
Key findings
Six key hub genes were discovered: HSP90AA1 and SRC, PIK3CA and JAK2, PTK2 and MET.
Piperine bound strongly to HSP90AA1 at -7.2 kcal/mol and to JAK2 at -7.5 kcal/mol, close to the standard treatment Tofacitinib at -7.5 kcal/mol.
Embelin showed a positive affinity with HSP90AA1 at -6.1 kcal/mol and with JAK2 at -5.8 kcal/mol.
Why it matters
- The authors say the data indicate that the two compounds may have antiarthritic properties, by regulating inflammatory and immunological pathways at several targets.
- The work used network pharmacology together with molecular docking, on targets drawn from databases.
How to cite
Sulaiman Ahmad, Shaikh Mahmad kaif, Shaikh Mehmood Dawood. Multi-Target Pharmacological Evaluation of Embelin and Piperine against Rheumatoid Arthritis: A Network Pharmacology and Molecular Docking Study. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):45-55. https://doi.org/10.56511/jipbs.2026.13106
- The article at doi.org (the publisher's page and PDF)
- The article on the journal's site
- The journal at the ISSN Portal (ISSN 2349-2759)